Padma Malyala
Chief Technology Officer nChroma Bio
Padma Malyala serves as Chief Technology Officer at nChroma Bio, bringing over 20 years of expertise in drug development, formulation, and analytical sciences. She joined nChroma following her role as Senior Vice President of Technical Development at Chroma Medicine, where she led technical strategy through its merger with Nvelop Therapeutics.
Padma has deep expertise in gene editing technologies, particularly in developing and optimizing delivery systems for precision genetic medicines. Prior to Chroma Medicine, she was Vice President of Formulation and Analytical Development at Verve Therapeutics, where she led drug product development for GalNAc-LNPs in gene editing applications. Earlier in her career, she held leadership roles at Novartis, MedImmune (AstraZeneca), and GSK, contributing to the development and advancement of vaccines, biologics, and gene therapies from early-stage research through clinical trials.
An inventor on multiple patents, Padma has contributed to innovations in RNA and gene editing technologies, iLipids for LNPs, vaccine adjuvants, and novel delivery systems.
Padma holds a BS in Pharmaceutical Sciences and an MS in Pharmaceutical Chemistry from Andhra University in India.
Seminars
Wednesday 8th April 2026
Roundtable Discussion: Mitigating Batch-to-Batch Variability Through Reproducible Process Controls & In- Process Monitoring
12:00 pm
- What are the main process conditions and impurities driving batch-to-batch variability during LNP scale-up?
- At which critical points in the manufacturing process should in-process analytics be implemented for real-time quality monitoring?
- How can process controls be designed to ensure reproducibility and consistency during scale up and across batches?
Wednesday 8th April 2026
Chair’s Opening Remarks
8:50 am
